J&J inks vaccine licensing deal with Aspen, paving the way for Africa's first local COVID-19 shot
South Africa’s Aspen has clinched its COVID-19 vaccine licensing deal with Johnson & Johnson in a move the company last year said could be a “game-changer” on the path to Africa’s vaccine sovereignty. Under the deal, Aspen will be able to manufacture and distribute J&J’s COVID shot in Africa, with the goal to boost COVID-19 vaccination rates across the continent, J&J said in a release. Specifically, the South African manufacturer will receive drug substances from J&J, which it will use to produce finished, Aspen-branded vaccines for the African public sector. Aspen will make the shots available to all 55 African Union member states, plus multilateral organizations supporting Africa’s COVID-19 vaccination efforts, such as the African Vaccine Acquisition Trust and the COVAX Facility.
View the full story here: https://www.fiercepharma.com/pharma/johnson-johnson-locks-vaccine-licensing-deal-aspen-teeing-africas-first-local-covid-19-shot